Cargando…
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by no means curative but clearly have a favorable impa...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531602/ https://www.ncbi.nlm.nih.gov/pubmed/33072773 http://dx.doi.org/10.3389/fmed.2020.00539 |